Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01531153
Recruitment Status : Completed
First Posted : February 10, 2012
Last Update Posted : August 5, 2016
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mehmet Sofuoglu, Yale University

Brief Summary:

Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use.

Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.

Condition or disease Intervention/treatment Phase
Addiction Drug: Galantamine Drug: Placebo Not Applicable

Detailed Description:

This will be a double-blind, placebo-controlled, randomized clinical trial. One hundred and twenty cocaine-dependent men and women will be randomized to one of three treatment groups: placebo (n=40), 8 mg/day (n=40), and 16 mg/day (n=40) of extended release (ER) galantamine. An urn randomization will be used to balance the groups for gender, severity of cocaine use (measured by days of cocaine use), baseline cognitive functioning [determined via the Shipley Institute of Living Scale (SILS)], and smoking status. Gender and severity of cocaine use have been shown to predict treatment responses in cocaine users (76). Similarly, balancing the treatment groups for baseline cognitive functioning, assessed with the SILS scores, will minimize the influence of baseline differences on cognitive outcomes (77, 78). Smoking status is also an important baseline variable, given galantamine's actions on nicotinic receptors and its potential efficacy for smoking cessation (65). The initial dose of galantamine will be 8 mg/day as a single dose, as recommended for clinical use. For those assigned to 16 mg/day, the dose of galantamine will be increased to 16 mg at the end of week 4. Treatment groups will remain on their full dosage through week 13. All participants will receive contingency management (CM) targeting treatment compliance. In three previous cocaine pharmacotherapy trials using bupropion, desipramine or levodopa, medication efficacy on cocaine use was evident only when medications were combined with CM, but not with standard care (79-81). These findings provide a strong rationale for using CM in our clinical trial.

Recruitment is continuing. This protocol was amended as of May 2014 to come to one dispensing visit and up too, two clinic visits. The payment has changed from gift cards to cash. This change should help increase the number of completers.

Currently there are 40 completers with 9 active and 6 in follow up phase. The follow up phase ended June 2016. Currently in analysis.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
Study Start Date : September 2011
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Sugar Pill
Sugar Pill will be compared with the active medication Galantamine
Drug: Placebo
Placebo dose.
Other Name: Sugar Pill

Active Comparator: Galantamine
Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
Drug: Galantamine
8mg or 16mg
Other Names:
  • Razadyne
  • Razadyne ER

Primary Outcome Measures :
  1. Urine Toxicology [ Time Frame: 2 times per week for 12 weeks. Also given at 1,3,6 month followup sessions. ]
    Cocaine urine toxicology will be assessed up to two times per week for 12 weeks. This will also be given at the 1, 3 and 6 month follow up period.

Secondary Outcome Measures :
  1. Heart Rate [ Time Frame: once a day for up to two days over 12 Weeks ]

  2. Blood Pressure [ Time Frame: 2 times a week for 12 weeks ]
    Blood Pressure is taken for safety reasons

  3. CANTAB RVIP measure [ Time Frame: Given at weeks 0, 4 8 and 12. Also given at followup month 1, 3 and 6. ]
    RVIP is a computerized measure of attention. This is given at baseline and every 4 weeks over the course of the 12-week study.

  4. CANTAB SST [ Time Frame: Given at weeks 0, 4 8 and 12. Also given at followup month 1, 3 and 6. ]
    This is the CANTAB SST measure which evaluates response inhibition.

  5. Stroop [ Time Frame: Given at weeks 0, 4 8 and 12. Also given at followup month 1, 3 and 6. ]
    A computerized Stroop task.

  6. Digit Span [ Time Frame: Given at weeks 0, 4 8 and 12. Also given at followup month 1, 3 and 6. ]
    A paper and pencil digit span task to assess short-term memory.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and females, between the ages of 18 and 60
  2. Are using cocaine more than once per week in the previous 30 days, provide a cocaine-positive urine specimen at screening, and fulfill criteria for current cocaine dependence according to DSM-IV
  3. For women of child-bearing age, have a negative pregnancy test at screening, agree to adequate contraception to prevent pregnancy, and agree to have monthly pregnancy tests
  4. Are fluent in English and have a 6th grade or higher reading level; AND
  5. Can commit to at least 13 weeks of treatment and are willing to be randomized to treatment

Exclusion Criteria:

  1. Meet DSM-IV psychiatric classifications for lifetime schizophrenia or bipolar disorder, or have a depressive or anxiety disorder with current use of a prescribed psychotropic medication that cannot be discontinued
  2. Current DSM-IV diagnosis of drug or alcohol dependence (other than cocaine, or tobacco)
  3. Demonstrate significant medical conditions, including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal deficit and cardiac rhythm disturbances or any other medical conditions that the study physician deems contraindicated for galantamine treatment
  4. Use of other medications including:

    • drugs that slow heart rate (e.g., beta-blockers), which may increase the risk of bradycardia and atrioventricular (AV) block and
    • non-steroidal anti-inflammatory drugs (NSAIDs); increased potential for developing ulcers/active or occult gastrointestinal bleeding
  5. Have a screening liver function test (AST or ALT) greater than 3 times normal; OR
  6. Known allergy or adverse reaction to galantamine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01531153

United States, Connecticut
Department of Veterans Affairs
West Haven, Connecticut, United States, 06516
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D. Yale University

Responsible Party: Mehmet Sofuoglu, Principle Investigator, Yale University Identifier: NCT01531153     History of Changes
Other Study ID Numbers: 1007007119
R01DA029577 ( U.S. NIH Grant/Contract )
First Posted: February 10, 2012    Key Record Dates
Last Update Posted: August 5, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Mehmet Sofuoglu, Yale University:
Cocaine use decreases, increases or stays the same

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Cholinergic Agents
Autonomic Agents
Nootropic Agents